Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen/Repellent Comments Stress Aligning FDA, EPA Label Regs

This article was originally published in The Tan Sheet

Executive Summary

FDA should amend the sunscreen monograph to include a subpart for combination insect repellent/sunscreen drug products and work with the Environmental Protection Agency to align the agencies' regulations for the products, Avon says
Advertisement

Related Content

Dual Label Meets Repellent/Sunscreen Requirements By FDA, EPA – Chattem
Dual Label Meets Repellent/Sunscreen Requirements By FDA, EPA – Chattem
Dual Label Meets Repellent/Sunscreen Requirements By FDA, EPA – Chattem
Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity
Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity
Sunscreen/Insect Repellent Combinations Should Be Monographed – CTFA
FDA Mulls Adding Insect Repellent Combinations To Sunscreen Monograph
FDA Mulls Adding Insect Repellent Combinations To Sunscreen Monograph

Topics

Advertisement
UsernamePublicRestriction

Register

PS100669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel